MOFSL stays bullish on Sun Pharma; sees 16% upside on innovation pipeline

August 3, 2026

Sun Pharma’s June quarter results met analyst expectations, signaling future growth. The company is expanding its specialty and innovative medicines portfolio significantly. Strategic initiatives like semaglutide launches and the Organon acquisition are key drivers. Despite US generics pressure, domestic business and specialty products show strong momentum. Analysts maintain a positive outlook, anticipating substantial growth from these ventures.

More To Explore

ITC shares gain 3% after Q1 results. Here’s why Nomura upgraded the stock to Buy

ITC shares rose 2% after the FMCG major reported June-quarter results, despite a 27% YoY decline in standalone net profit. Revenue grew 28%, while Nomura

August 3, 2026

Bajaj Finserv shares rise over 2% after Q1 earnings. Here’s why Motilal Oswal upgrades to Buy, raises target price

Bajaj Finserv shares climbed after reporting a 12% net profit increase for Q1 FY27. Revenue from operations grew nineteen percent year-on-year, and interest income also

August 3, 2026

Advertiser Disclosure

Great-investor.com helps users across the globe to find out The latest news, Guides, and Info about finance and investments. Furthermore, our content and research teams do not participate in any advertising planning nor are they permitted access to advertising campaign data.

Disclaimer

It is our organization’s primary mission to provide reviews, commentary, and analysis that are unbiased and objective. While great-investor.com has some data verified by industry participants, it can vary from time to time. Operating as an online business, this site may be compensated through third party advertisers. Our receipt of such compensation shall not be construed as an endorsement or recommendation by great-investor.com, nor shall it bias our reviews, analysis, and opinions. Please see our General Disclaimers for more information.

The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.

Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003